Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies
Amsterdam, The Netherlands , July 22, 2021 – Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced the signature of a...
VarmX to Present New Data on Lead Compound, VMX-C001,
at the ISTH 2021 Virtual Congress
Leiden, The Netherlands, 19 July 2021 - VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that new preclinical data on VMX-C001 has been selected to be presented during an oral...
Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer
Leiden, The Netherlands, June 30, 2021 – Azafaros B.V. today announced that Stefano Portolano, M.D., has joined Azafaros as Chief Executive Officer (CEO) and has concurrently been appointed to the Board of Directors of the company. Dr. Portolano is an experienced...
Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent’s Pipeline
AMSTERDAM, NETHERLANDS – June 29, 2021 – Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today...
VectorY raises €31 million in seed financing to develop next-generation gene therapies aimed at muscular and CNS disorders
Amsterdam, The Netherlands, 15 June 2021 – VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, today announces the...
VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board
Leiden, The Netherlands, 15 June 2021 - VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Jan Öhrström, as Chief Executive Officer, and of Dr. Alex Gold to the...
Confo Therapeutics Establishes Medical Advisory Board
Ghent, Belgium – June 10, 2021 - Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of...
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
Munich, Germany, May 4, 2021 – CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L’Huillier as Chief Executive Officer (CEO), effective May 17, 2021. Dr. Phil L’Huillier brings over two...
BGV Announces New Investment with i2020 Accelerator and Orbimed in Neurology-focused Therapeutics
Naarden, The Netherlands, 22 April 2021. - BioGeneration Ventures (BGV), together with i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, and OrbiMed have announced a new startup investment in Brenig Therapeutics, a...
BGV Appoints Head of Communications
Naarden, The Netherlands, 16 April 2021 – BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma has announced the appointment of Laura Asbjornsen as its Head of Communications. As lead for communications at both BGV and its platform partner...